Skip to main content

Table 3 First line symptomatic treatment and knowledge of the EAACI/GA2LEN/EDF/WAO guideline according to specialties

From: Knowledge and management of chronic spontaneous urticaria in Latin America: a cross-sectional study in Ecuador

 

GPs

A/D

Others

Peds

IM

Total

Chi square

Aware of guideline

Not aware of guideline

Chi square

n

%

n

%

n

%

n

%

n

%

n

%

p value

n

%

n

%

p value

fgAHs (normal doses)

9

7.7

1

3.7

1

20.0

12

42.9

5

20.8

28

13.9

0.000

5

10.0

22

15.1

0.369

fgAHs (highest doses)

9

7.7

2

7.4

0

0.0

3

10.7

0

0.0

14

7.0

0.578

7

14.0

7

4.8

0.029

sgAHs (normal doses)

34

29.1

20

74.1

3

60.0

8

28.6

9

37.5

74

36.8

0.000

23

46.0

50

34.2

0.138

sgAHs (highest doses)

9

7.7

14

51.9

0

0.0

3

10.7

0

0.0

26

12.9

0.000

14

28.0

12

8.2

0.000

Combination of fgAHs

2

1.7

0

0.0

0

0.0

1

3.6

1

4.2

4

2.0

0.802

1

2.0

2

1.4

0.754

Combination of sgAHs

24

20.5

1

3.7

0

0.0

0

0.0

7

29.2

32

15.9

0.007

2

4.0

30

20.5

0.006

fgAHs plus sgAHS

5

4.3

1

3.7

0

0.0

0

0.0

0

0.0

6

3.0

0.650

3

6.0

3

2.1

0.162

fgAHs plus AH2

2

1.7

2

7.4

0

0.0

0

0.0

0

0.0

4

2.0

0.261

1

2.0

3

2.1

0.981

sgAHS plus AH2

14

12.0

2

7.4

0

0.0

0

0.0

3

12.5

19

9.5

0.319

1

2.0

18

12.3

0.033

fgAHs plus alk

4

3.4

1

3.7

0

0.0

1

3.6

2

8.3

8

4.0

0.825

3

6.0

4

2.7

0.284

sgAHs plus alk

6

5.1

6

22.2

0

0.0

2

7.1

1

4.2

15

7.5

0.037

9

18.0

6

4.1

0.001

fgAHs plus AH2 plus alk

2

1.7

0

0.0

0

0.0

1

3.6

0

0.0

3

1.5

0.789

0

0.0

3

2.1

0.307

sgAHs plus AH2 plus alk

7

6.0

7

25.9

0

0.0

2

7.1

0

0.0

16

8.0

0.005

9

18.0

7

4.8

0.003

Ciclosporine

8

6.8

2

7.4

0

0.0

2

7.1

1

4.2

13

6.5

0.958

3

6.0

8

5.5

0.890

Dapsone

3

2.6

7

25.9

0

0.0

2

7.1

2

8.3

14

7.0

0.001

8

16.0

6

4.1

0.005

Hydroxychloroquine

1

0.9

3

11.1

0

0.0

1

3.6

0

0.0

5

2.5

0.034

2

4.0

3

2.1

0.451

Ketotifen

2

1.7

1

3.7

0

0.0

0

0.0

1

4.2

4

2.0

0.789

1

2.0

2

1.4

0.754

Methotrexate

3

2.6

6

22.2

0

0.0

0

0.0

0

0.0

9

4.5

0.000

8

16.0

1

0.7

0.000

Omalizumab

3

2.6

4

14.8

0

0.0

0

0.0

0

0.0

7

3.5

0.013

6

12.0

1

0.7

0.000

Oral cortico-steroids

53

45.3

11

40.7

2

40.0

13

46.4

14

58.3

93

46.3

0.761

20

40.0

72

49.3

0.255

Sulfasalazine

0

0.0

0

0.0

0

0.0

0

0.0

1

4.2

1

0.5

0.116

0

0.0

1

0.7

0.557

Tricyclic antidepressants

1

0.9

0

0.0

0

0.0

0

0.0

0

0.0

1

0.5

0.949

0

0.0

1

0.7

0.557

Others

0

0.0

6

22.2

1

20.0

1

3.6

0

0.0

8

4.0

0.000

3

6.0

5

3.4

0.427

  1. fgAHs first generation antihistamines, sgAHs second generation antihistamines, AH-2 anti-H2, ALK anti-leukotriene